Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

PharmaJet spotlights Nature publication on Stratis IM System benefits

Closely held PharmaJet has announced that the peer-reviewed journal Nature has published findings from a U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) Phase 1 trial, demonstrating that the...

December 10, 2024

Developments

Akoya and NeraCare enter agreement to develop and commercialize Immunoprint test for melanoma

Akoya Biosciences (NASDAQ:AKYA) announced that it has entered into an exclusive global licencing agreement with NeraCare to develop and commercialize NeraCare’s Immunoprint test for guiding early-stage melanoma...

December 10, 2024

Developments

IN8bio reports sustained PFS in INB-100 trial for HSCT patients

IN8bio (NASDAQ:INAB) shared updated data showcasing continued progression-free survival (PFS) from its Phase 1 trial of INB-100 in older patients with hematologic malignancies undergoing haploidentical stem cell...

December 10, 2024

Developments

Profound Medical gains media attention for its incision- and radiation-free TULSA treatment for prostate cancer and/or BPH

Profound Medical’s (NASDAQ:PROF; TSX:PRN) CEO, Arun Menawat, recently sat down with Fierce Biotech to discuss how TULSA-PRO is revolutionizing prostate disease treatment. In the interview, Dr. Menawat noted...

December 9, 2024

Developments

Immunovia announces positive results and strong accuracy of next-gen test for PDAC

Immunovia (STO:IMMNOV) has announced the completion of its CLARITI study, demonstrating positive outcomes and strong accuracy in the clinical validation of its next-generation test for the early detection of pancreatic...

December 9, 2024

Developments

BioNxt achieves milestones for BNT23001 in MS

BioNxt Solutions (CSE:BNXT; OTC PINK:BNXTF; FSE:BXT) has announced that key milestones have been achieved in the development of BNT23001 for the treatment of multiple sclerosis (MS). BNT23001 is BioNxt’s proprietary...

December 9, 2024

Developments

Innate to receive up to $7.9 million from IFLI to advance IPH6501 in FL

Innate Pharma (Euronext Paris:IPH; NASDAQ:IPHA) and the Institute for Follicular Lymphoma (IFLI) have announced a collaboration agreement to clinically evaluate the potential of Innate’s IPH6501 in follicular lymphoma...

December 6, 2024

Developments

FDA grants clearance for Nanox.ARC expanding application to pulmonary and general use

Nanox Imaging (NASDAQ:NNOX) has announced that its Nanox.ARC stationary X-ray system has received 510(k) clearance from the FDA, allowing general use including the human musculoskeletal system, pulmonary, intra...

December 6, 2024

Developments

FDA grants RMAT for combination of Affimed’s acimtamig and Artiva’s AlloNK

Affimed (NASDAQ:AFMD) announced that the FDA has granted regenerative medicine advanced therapy (RMAT) designation to its combination therapy involving Affimed’s innate cell engager (ICE) acimtamig, and Artiva...

December 5, 2024

Developments

Nkarta receives IND clearance for IST in MG; launches enrollment of Ntrust-2 trial

Nkarta (NASDQ:NKTX) announced the clearance of an investigational new drug clearance (IND) application for its investigator-sponsored trial (IST) evaluating NKX019 in patients with myasthenia gravis (MG), alongside the...

December 5, 2024

Developments

Cartesian reports promising results from Phase 2b trial of Descartes-08 in MG

Cartesian Therapeutics (NASDAQ:RNAC) announced updated efficacy and safety data from its Phase 2b trial of Descartes-08 in myasthenia gravis (MG), showing deep, durable responses without the need for chemotherapy. The...

December 4, 2024

Developments

Medicus enters agreement with Swanielle to expand Phase 2 trial in APAC

Medicus Pharma (NASDAQ:MDCX) (TSXV:MDCX) announced a collaborative agreement with Swanielle to explore the expansion of its SKNJCT-003 Phase 2 clinical study for the treatment of basal cell carcinoma in the Asia-Pacific...

December 2, 2024

Developments

FDA accepts Revelation’s IND for Gemini in CKD

Revelation Biosciences (NASDAQ:REVB) announced that the FDA has accepted its investigational new drug (IND) application for Gemini in chronic kidney disease (CKD). The company notes that the milestone enables the launch...

December 2, 2024

Developments

Elite launches generic hydrocodone and acetaminophen tables for pain management

Elite Pharmaceuticals (OTCQB:ELTP) announced it has launched a generic version of Norco tablets, a combination of hydrocodone bitartrate and acetaminophen for pain management. The generic hydrocodone bitartrate and...

December 2, 2024

Developments

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Profound Medical (NASDAQ:PROF; TSX:PRN) announced a definitive co-sales and co-marketing agreement with Siemens Healthineers (XETRA:SHL) pursuant to which the companies will commercialize a new MRI-guided prostate...

December 2, 2024

Developments

CervoMed’s stock rises as FDA grants ODD to neflamapimod for dementia

CervoMed (NASDAQ:CRVO) announced that the FDA has granted orphan drug designation (ODD) to its lead investigational therapy, neflamapimod, for the treatment of frontotemporal dementia (FTD). Following the announcement...

November 28, 2024

Developments

Perimeter showcases ASBrS webinar focused on margin assessment using OCT during breast cancer surgery

Perimeter Medical Imaging AI (TSX-V: PINK; OTC: PYNKF) highlighted the November 26, 2024 webinar entitled, “Clearer Margins. Greater Confidence. Exploring the Benefits of OTC”, sponsored by the American Society of...

November 27, 2024

Developments

Profound Medical to unveil 3rd TULSA-AI module, ‘UA Alignment Assistant’, at upcoming medical meetings

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that it will unveil its third TULSA-AI software module, UA Alignment Assistant at the upcoming 110th Scientific Assembly and Annual Meeting of the Radiological Society...

November 26, 2024

Developments

MaaT meets Phase 1b primary endpoint for Maat003 in ALS

MaaT Pharma (EURONEXT: MAAT) announced that its IASO Phase 1b clinical trial, evaluating the safety and tolerability of multiple doses of MaaT003 in amyotrophic lateral sclerosis (ALS), has met its primary endpoint...

November 26, 2024

Developments

IMUNON reports outcome of end-of-Phase 2 FDA meeting for IMNN-001 in ovarian cancer

IMUNON (NASDAQ: IMNN) announced the results of its end-of-Phase 2 meeting with the FDA supporting investigational interleukin-12 (IL-12) immunotherapy IMNN-001 for the treatment of advanced ovarian cancer into a 500...

November 26, 2024

Developments

Ikonisys wins contract for Ikoniscope20 robotic microscope in Italy

Ikonisys Group (Euronext Paris:ALIKO) announced that its subsidiary, Hospitex, has been awarded a public tender to supply the innovative Ikoniscope20 robotic microscope to the Department of Pathological Anatomy in...

November 25, 2024

Developments

Enveric’s preclinical PK studies of EB-003 show oral bioavailability without hallucinogenic effects

Enveric Biosciences (NASDAQ:ENVB) announced the completion of preclinical pharmacokinetic (PK) studies of EB-003, which support its oral bioavailability and targeted non-hallucinogenic profile. EB-003 is a potential...

November 25, 2024

Subscribe